{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:23Z","timestamp":1791176843648,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.vaccine.2008.07.098","type":"journal-article","created":{"date-parts":[[2008,8,23]],"date-time":"2008-08-23T07:21:50Z","timestamp":1219476110000},"page":"5654-5661","source":"Crossref","is-referenced-by-count":37,"title":["Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model"],"prefix":"10.1016","volume":"26","author":[{"given":"Cara","family":"Usher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Tilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2008.07.098_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ijc.11719","article-title":"Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost","volume":"109","author":"Yang","year":"2004","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2008.07.098_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.098_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.098_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S0266462307080026","article-title":"Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France","volume":"24","author":"Bergeron","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vaccine.2008.07.098_bib5","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.098_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","article-title":"A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program","volume":"4","author":"Kulasingam","year":"2007","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2008.07.098_bib7","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1016\/j.vaccine.2007.05.061","article-title":"Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands","volume":"25","author":"Boot","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.098_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.vaccine.2007.10.056","article-title":"Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation","volume":"26","author":"Insinga","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.098_bib9","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1016\/j.vaccine.2007.05.058","article-title":"Cost-effectiveness of HPV 16, 18 vaccination in Brazil","volume":"25","author":"Goldie","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.098_bib10","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1016\/j.vaccine.2007.07.018","article-title":"Cost-utility analysis of vaccination against HPV in Israel","volume":"25","author":"Ginsberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.098_bib11","unstructured":"Belgian Health Care Knowledge Centre. HPV vaccination for the prevention of cervical cancer in Belgium. Health Technology Assessment. KCE report Vol. 64C, 2007. Available at: http:\/\/www.kce.fgov.be\/index_en.aspx?SGREF=9152&CREF=9997 [accessed May 19, 2008]."},{"key":"10.1016\/j.vaccine.2008.07.098_bib12","unstructured":"Danish Centre for Health Technology Assessment (DACEHTA). Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV)\u2014a health technology assessment. Health Technology Assessment 2007; 9 (1). Available at: http:\/\/www.sst.dk\/publ\/Publ2007\/MTV\/HPV\/HPV_vaccination_en.pdf [accessed June 25, 2008]."},{"key":"10.1016\/j.vaccine.2008.07.098_bib13","unstructured":"Norwegian Knowledge Centre for the Health Services. Cost-effectiveness of human papillomavirus (HPV) vaccination in Norway. Health Technology Assessment Nr 12-2007. Available at: http:\/\/www.kunnskapssenteret.no\/filer\/rapport_0712_HPVdel2.pdf [accessed January 8, 2008]."},{"key":"10.1016\/j.vaccine.2008.07.098_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vaccine.2008.07.098_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2008.07.098_bib16","doi-asserted-by":"crossref","unstructured":"Layte R, McGee H, Quail A, Rundle K, Cousins G, Donnelly C, Mulcahy F, Conroy R. The Irish Study of Sexual Health and Relationships (ISSHR). Published by the Crisis Pregnancy Agency and the Department of Health and Children. October 2006. Available at: http:\/\/www.crisispregnancy.ie\/pub\/isshrmainii.pdf [accessed May 15, 2008].","DOI":"10.1037\/e535732013-001"},{"key":"10.1016\/j.vaccine.2008.07.098_bib17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2008.07.098_bib18","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2008.07.098_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2008.07.098_bib20","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/ijc.23034","article-title":"HPV genoptypes in CIN 2\u20133 lesions and cervical cancer: a population-based study","volume":"121","author":"Sigurdsson","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2008.07.098_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.bjc.6603210","article-title":"ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial","volume":"95","author":"Kitchener","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2008.07.098_bib22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH718>3.0.CO;2-H","article-title":"Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features","volume":"192","author":"Butler","year":"2000","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2008.07.098_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0046-8177(98)90120-4","article-title":"Human papillomavirus and mixed epithelial tumors of the endometrium","volume":"29","author":"O\u2019Leary","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.vaccine.2008.07.098_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jcp.51.8.576","article-title":"Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix","volume":"51","author":"O\u2019Leary","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.vaccine.2008.07.098_bib25","first-page":"675","article-title":"Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations","volume":"12","author":"Skyldberg","year":"1999","journal-title":"Mod Pathol"},{"key":"10.1016\/j.vaccine.2008.07.098_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/09674845.2007.11732750","article-title":"Human papillomavirus prevalence and genotypes in an opportunistically screened Irish female population","volume":"64","author":"Keegan","year":"2007","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.vaccine.2008.07.098_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cct.2006.04.001","article-title":"Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): trial design","volume":"27","author":"Cotton","year":"2006","journal-title":"Cont Clin Trials"},{"key":"10.1016\/j.vaccine.2008.07.098_bib28","unstructured":"Health Service Executive (HSE). Ready reckoner of acute hospital inpatient activity and costs (summarised by DRG) relating to 2005 costs and activity. Casemix Unit of the National Hospitals Office. Annual Report 2007, Part 3."},{"key":"10.1016\/j.vaccine.2008.07.098_bib29","doi-asserted-by":"crossref","unstructured":"Rash R, Prenderville W, Byrne P, Stratton J, Redmond S. The cost of treating and managing abnormal cervical conditions in Ireland. Abstract No. PCN39, Presented at ISPOR 10th annual European congress, Dublin, Ireland, October 20\u201323, 2007.","DOI":"10.1016\/S1098-3015(10)65197-2"},{"key":"10.1016\/j.vaccine.2008.07.098_bib30","unstructured":"National Immunisation Uptake Statistics (Summary)\u2014Q1 1999\u2014Q4 2007. http:\/\/www.ndsc.ie\/hpsc\/A-Z\/VaccinePreventable\/Vaccination\/ImmunisationUptakeStatistics\/ImmunisationUptakeStatisticsSummary\/File,954,en.pdf [accessed June 2008]."},{"key":"10.1016\/j.vaccine.2008.07.098_bib31","unstructured":"Tilson L, Thornton L, O\u2019Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health. Advanced on-line access December 26, 2007."},{"issue":"September\/October (5)","key":"10.1016\/j.vaccine.2008.07.098_bib32","article-title":"Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland","volume":"11","author":"Tilson","year":"2008","journal-title":"Val Health"},{"key":"10.1016\/j.vaccine.2008.07.098_bib33","unstructured":"European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. Stockholm, January 2008. Available at: http:\/\/ecdc.europa.eu\/pdf\/HPV_report.pdf [Accessed April 2, 2008]."},{"issue":"4","key":"10.1016\/j.vaccine.2008.07.098_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/hec.1068","article-title":"Evidence synthesis, parameter correlation and probabilistic sensitivity analysis","volume":"15","author":"Ades","year":"2006","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.vaccine.2008.07.098_bib35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08010128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08010128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T11:08:38Z","timestamp":1557745718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08010128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":35,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0264410X08010128"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.07.098","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}